08:00 , Mar 3, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Hypoxia-inducible factor prolyl hydroxylase 1 (EGLN2; HIF-PH1; PHD1)

Cardiovascular disease INDICATION: Myocardial infarction (MI) Mouse studies suggest inhibiting EGLN2 could help prevent cardiac injury in patients at risk of MI. In a mouse model of ischemia/reperfusion injury-induced MI, pretreatment or treatment with an...
07:00 , Jun 19, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Other

Indication Target/marker/pathway Summary Licensing status Publication and contact information Other Poisoning Hypoxia-inducible factor prolyl hydroxylase 1 (EGLN2; HIF-PH1; PHD1); PHD2 (EGLN1; HIF-PH2); PHD3 (EGLN3; HIF-PH3) Mouse studies suggest pan-PHD inhibitors could help prevent damage to...
08:00 , Nov 14, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Inflammation

Indication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation Inflammation Hypoxia-inducible factor 1a subunit inhibitor (HIF1AN; FIH1); hypoxia-inducible factor prolyl hydroxylase 1 (EGLN2; HIF-PH1; PHD1) In vitro and mouse studies suggest inhibiting HIF1AN and...
07:00 , Oct 17, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes Hypoxia-inducible factor prolyl hydroxylase 3 (EGLN3; HIF-PH3; PHD3) Mouse studies suggest liver-specific inhibition of PHD3 could help treat type...
07:00 , Apr 16, 2012 |  BioCentury  |  Emerging Company Profile

Aerpio: Stanching the leak

Anemia company Akebia Therapeutics Inc. spun out Aerpio Therapeutics Inc. in January to develop a Tie2 activator that not only could be more effective than VEGF inhibitors for diabetic macular edema, but also could treat...
08:00 , Nov 12, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Cyclin D1 (CCND1; BCL1); hypoxia-inducible factor prolyl hydroxylase 1 (EGLN2; HIF-PH1; PHD1) Studies in mice and in cell culture suggest that inhibiting EGLN2 could...
07:00 , Oct 8, 2009 |  BC Innovations  |  Targets & Mechanisms

Hitting HIF1 in cancer

Hypoxic regions in solid tumors can help trigger angiogenesis and invasion but are hard to attack with radiotherapy and chemotherapeutics because the oxygen-deprived areas are distant from any blood supply. Researchers at The Johns Hopkins...
07:00 , Aug 24, 2009 |  BioCentury  |  Emerging Company Profile

Akebia: HIF, HIF, Hooray

Injectable erythropoiesis-stimulating agents, though still standard of care for anemia, dramatically increase the concentration of erythropoietin, which can lead to cardiovascular and thromboembolic events over time. Akebia Therapeutics Inc. believes its oral lead anemia compound...
08:00 , Jan 15, 2009 |  BC Innovations  |  Targets & Mechanisms

Arresting infant retinopathy

Researchers at the Cleveland Clinic have found that activating hypoxia-inducible factor can prevent the progression of retinopathy in premature infants, which results in blindness if left unchecked. The findings, reported in the Proceedings of the...
08:00 , Jan 15, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Ophthalmic disease

This week in therapeutics Indication Target/ marker/ pathway Summary Licensing status Publication and contact information Ophthalmic disease Retinopathy of prematurity Hypoxia-inducible factor 1 (HIF1A; HIF1); endothelial PAS domain protein 1 (EPAS1; HIF2A); hypoxia-inducible factor prolyl...